Pharmaceutical News

RSS

Allos reports net loss of $20.0 million for second-quarter 2010

Allos Therapeutics, Inc. today reported its financial results and business highlights for the quarter and six months ended June 30, 2010.

28 Jul 2010

New £50M fund made available to help patients get access to innovative new cancer drugs

The government has announced a new £50 million fund to improve access to cancer drugs until the new Cancer Drugs Fund comes into effect in April 2011.

28 Jul 2010

Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court

Baum Hedlund announces that Taiwanese hemophiliacs infected by HIV-contaminated medications have petitioned the United States Supreme Court to allow their claims to proceed in California. Their suits contend that California-based defendants illegally used paid plasma donors at high risk for transmitting blood-borne diseases (i.v. drug users, prisoners, and promiscuous urban gay males) to make injected anti-hemophilia medications.

28 Jul 2010

PhRMA asks FDA to be more straightforward on safeguards it wants to fight drug risks

The pharmaceutical industry trade group PhRMA said Monday that the Food and Drug Administration should do a better job of explaining additional safeguards it mandates against certain drugs when it issues warnings, Reuters reports.

28 Jul 2010

FDA accepts for filing Cladribine Tablets NDA for MS

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).

28 Jul 2010

Morphine blocks new blood vessel and tumor growth: Study

Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1α/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.

28 Jul 2010

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2010. The Company reported a net loss of $25.5 million, or $0.31 per share (basic and diluted), for the second quarter of 2010 compared with a net loss of $14.9 million, or $0.19 per share (basic and diluted), for the second quarter of 2009.

28 Jul 2010

New York Times examines questions left unanswered by microbicide trial

The New York Times examines a set of questions raised by news out of the International AIDS Conference-AIDS 2010 last week that a microbicide gel containing the antiretroviral tenofovir used by women before and after sex helped reduce their risk of HIV infection by 39 percent.

28 Jul 2010

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

Genzyme Corp.today said it welcomed the Centers for Medicare and Medicaid Services' decision not to include oral medications without IV equivalents in Medicare's End Stage Renal Disease patient benefit. According to the final rule, these medications, including Genzyme's Renvela (sevelamer carbonate), will not be included in the bundle until January 1, 2014.

28 Jul 2010

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

The National Comprehensive Cancer Network has been awarded two individual $2 million grants from GlaxoSmithKline to support clinical studies of ofatumumab (Arzerra®, GlaxoSmithKline) in the treatment of hematologic malignancies and pazopanib (Votrient®, GlaxoSmithKline) in the treatment of solid tumors.

28 Jul 2010

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Merck, known outside the U.S. and Canada as MSD, and Sinopharm today announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting and marketing Merck's pharmaceutical products in China.

28 Jul 2010

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

VillageReach announces $5.6M program to strengthen national health system in Mozambique

VillageReach, the Seattle-based social enterprise that increases access to healthcare for remote, last mile communities in low-income countries, today announced a $5.6 million program to strengthen the national health system in Mozambique. Contributions for the six-year program total $1.2 million to date.

27 Jul 2010

Momenta Pharmaceuticals provides update on generic Lovenox ANDA litigation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today provided an update regarding a lawsuit that Sanofi-Aventis U.S. LLC filed in the United States District Court for the District of Columbia against the U.S. Food and Drug Administration (FDA), Margaret A. Hamburg, Commissioner of Food and Drugs, and Kathleen Sebelius, Secretary of Health and Human Services.

27 Jul 2010

Researchers reveal biological rationale for why corticosteroids help people with lupus

Researchers at UT Southwestern Medical Center have uncovered the biological rationale for why large doses of corticosteroids given repeatedly over several weeks may help individuals with lupus, a chronic inflammatory disease that affects more than 1 million people in the U.S.

27 Jul 2010

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

27 Jul 2010

Glaxosmithkline to implement new compensation program for sales professionals

GlaxoSmithKline today confirmed that it will implement a new system for evaluating and compensating its sales professionals beginning in 2011.Under the new system, bonuses for sales professionals who work directly with healthcare professionals and other customers will no longer be based on individual achievement of sales targets, but will be based primarily on the service they deliver to customers. Bonuses will be determined, in part, by customer feedback, and by a sales professional's adherence to the company values of transparency, integrity, respect and patient-focus.

27 Jul 2010

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

27 Jul 2010

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

Iverson Genetic Diagnostics today announced the company has received approval from CMS to conduct a WARFARIN Clinical Study. The two-year (2) study will assess the impact of genetic information in calculating doses and the changes in the rate of adverse events when initiating Warfarin drug therapy. These changes will be compared against doses initiated without genetic data. The randomized and blinded, multi-center study will involve more than 7000 participants at over 50 sites nationwide.

27 Jul 2010

ProtAffin signs manufacturing contract with CMC Biologics for COPD drug PA401

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today announced it has signed a manufacturing contract with CMC Biologics' Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of chronic obstructive pulmonary disease (COPD). The contract will cover manufacture and supply of PA401 for preclinical development and early clinical development in COPD and related respiratory indications.

27 Jul 2010

Pharmaceutical News

Allos reports net loss of $20.0 million for second-quarter 2010

New £50M fund made available to help patients get access to innovative new cancer drugs

Taiwanese hemophiliacs infected by HIV-contaminated medications petition US Supreme Court

PhRMA asks FDA to be more straightforward on safeguards it wants to fight drug risks

FDA accepts for filing Cladribine Tablets NDA for MS

Morphine blocks new blood vessel and tumor growth: Study

Regeneron second-quarter total revenues increase to $115.9 million

New York Times examines questions left unanswered by microbicide trial

Genzyme accepts CMS decision for delaying Renvela administration to dialysis patients

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Antigenics announces positive results of AG-707 genital herpes vaccine

VillageReach announces $5.6M program to strengthen national health system in Mozambique

Momenta Pharmaceuticals provides update on generic Lovenox ANDA litigation

Researchers reveal biological rationale for why corticosteroids help people with lupus

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

Glaxosmithkline to implement new compensation program for sales professionals

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Iverson Genetic Diagnostics receives CMS approval for Warfarin clinical study

ProtAffin signs manufacturing contract with CMC Biologics for COPD drug PA401

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News